These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26299750)

  • 41. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity.
    Farrance CE; Chichester JA; Musiychuk K; Shamloul M; Rhee A; Manceva SD; Jones RM; Mamedov T; Sharma S; Mett V; Streatfield SJ; Roeffen W; van de Vegte-Bolmer M; Sauerwein RW; Wu Y; Muratova O; Miller L; Duffy P; Sinden R; Yusibov V
    Hum Vaccin; 2011; 7 Suppl():191-8. PubMed ID: 21266847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.
    Scaria PV; Chen BB; Rowe CG; Alani N; Muratova OV; Barnafo EK; Lambert LE; Zaidi IU; Lees A; Rausch KM; Narum DL; Duffy PE
    Vaccine; 2020 Jul; 38(34):5480-5489. PubMed ID: 32600913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
    Theisen M; Jore MM; Sauerwein R
    Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Blagborough AM; Musiychuk K; Bi H; Jones RM; Chichester JA; Streatfield S; Sala KA; Zakutansky SE; Upton LM; Sinden RE; Brian I; Biswas S; Sattabonkot J; Yusibov V
    Vaccine; 2016 Jun; 34(28):3252-9. PubMed ID: 27177945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.
    Scally SW; McLeod B; Bosch A; Miura K; Liang Q; Carroll S; Reponen S; Nguyen N; Giladi E; Rämisch S; Yusibov V; Bradley A; Lemiale F; Schief WR; Emerling D; Kellam P; King CR; Julien JP
    Nat Commun; 2017 Nov; 8(1):1568. PubMed ID: 29146922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
    Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
    Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study.
    Sharma B
    In Silico Biol; 2008; 8(3-4):193-206. PubMed ID: 19032156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.
    Kapoor N; Vanjak I; Rozzelle J; Berges A; Chan W; Yin G; Tran C; Sato AK; Steiner AR; Pham TP; Birkett AJ; Long CA; Fairman J; Miura K
    Biochemistry; 2018 Feb; 57(5):516-519. PubMed ID: 29323879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
    Baldwin SL; Roeffen W; Singh SK; Tiendrebeogo RW; Christiansen M; Beebe E; Carter D; Fox CB; Howard RF; Reed SG; Sauerwein R; Theisen M
    Vaccine; 2016 Apr; 34(19):2207-15. PubMed ID: 26994314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.
    Othoro C; Johnston D; Lee R; Soverow J; Bystryn JC; Nardin E
    Infect Immun; 2009 Feb; 77(2):739-48. PubMed ID: 19047411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.
    Jones RM; Chichester JA; Mett V; Jaje J; Tottey S; Manceva S; Casta LJ; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Mett V; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    PLoS One; 2013; 8(11):e79538. PubMed ID: 24260245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro.
    Sala KA; Nishiura H; Upton LM; Zakutansky SE; Delves MJ; Iyori M; Mizutani M; Sinden RE; Yoshida S; Blagborough AM
    Vaccine; 2015 Jan; 33(3):437-45. PubMed ID: 25454088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
    Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
    Front Immunol; 2020; 11():606266. PubMed ID: 33505395
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and protective potential of a Plasmodium spp. enolase peptide displayed on archaeal gas vesicle nanoparticles.
    Dutta S; DasSarma P; DasSarma S; Jarori GK
    Malar J; 2015 Oct; 14():406. PubMed ID: 26463341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.
    Stowers AW; Keister DB; Muratova O; Kaslow DC
    Infect Immun; 2000 Oct; 68(10):5530-8. PubMed ID: 10992450
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25.
    Quakyi IA; Miller LH; Good MF; Ahlers JD; Isaacs SN; Nunberg JH; Houghten RA; Keister DB; Coligan JE; Moss B
    Pept Res; 1995; 8(6):335-44. PubMed ID: 8838417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.
    Zhu D; Wu Y; McClellan H; Dai W; Rausch K; Jones D; Aebig J; Barnafo E; Butler B; Lambert L; Narum DL; Duffy PE
    Vaccine; 2017 May; 35(24):3232-3238. PubMed ID: 28479180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
    Pattnaik P; Shakri AR; Singh S; Goel S; Mukherjee P; Chitnis CE
    Vaccine; 2007 Jan; 25(5):806-13. PubMed ID: 17045706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.